Clinical Trial: The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title:

Brief Summary: Under the modern precise radiotherapy technology, clear the best dose volume limit index and the limit value for the primary level prevention of heart injury; clear best follow-up interval and measures for heart function of breast cancer patients, to achieve the secondary prevention of cardiac injury; explore combined cardiovascular specialist optimal treatment strategy for heart injury in the treatment of breast cancer, during the tertiary prevention of cardiac injury; put forward rationalization proposal for prevention, treatment and follow-up for breast cancer associated with heart injury.

Detailed Summary:
Sponsor: Ruijin Hospital

Current Primary Outcome: event free survival [ Time Frame: 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • event free survival [ Time Frame: 5 years ]
  • event free survival [ Time Frame: 10 years ]
  • overall survival [ Time Frame: 5 years ]
  • overall survival [ Time Frame: 10 years ]
  • relative change of value of serum cardiac biomarker [ Time Frame: 1 year ]
  • relative change of value of serum cardiac biomarker [ Time Frame: 5 years ]
  • relative change of left ventricular ejection fraction (LVEF) [ Time Frame: 1 year ]
  • relative change of LVEF [ Time Frame: 5 year ]
  • relative change of LVEF [ Time Frame: 10 year ]
  • score of life quality [ Time Frame: 1 year ]
  • score of life quality [ Time Frame: 5 years ]


Original Secondary Outcome: Same as current

Information By: Ruijin Hospital

Dates:
Date Received: October 19, 2016
Date Started: November 2016
Date Completion:
Last Updated: October 21, 2016
Last Verified: October 2016